Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | ADH1B | P00325 | 1/20 | 0.47 |
| ▸ | ADH1C | P00326 | 1/20 | 0.47 |
| ▸ | ADH1A | P07327 | 1/20 | 0.47 |
| ▸ | ADH7 | P40394 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156664 | 0.83 | MEN1 (0.56) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| SCHEMBL5181873 | 0.83 | THRB (0.56) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| Hydrochloric Acid SCHEMBL1252387 | 0.81 | MEN1 (0.54) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| Ammonia Solution, Strong SCHEMBL27486735 | 0.81 | MEN1 (0.54) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| Bicarbonate SCHEMBL23420914 | 0.80 | HDAC8 (0.64) | MEN1KMT2ATDP1HDAC8HDAC6 | |
| Bicarbonate SCHEMBL11577277 | 0.80 | HDAC8 (0.64) | MEN1KMT2ATDP1HDAC8HDAC6 | |
| SCHEMBL87424 | 0.79 | SPHK2 (0.65) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| SCHEMBL4602978 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| SCHEMBL19942807 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1ALDH1A1HDAC8 | |
| SCHEMBL12809838 | 0.79 | MEN1 (0.52) | MEN1KMT2ATDP1ALDH1A1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737831-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-05-22 | — | — | EP | disclosed |
| CN-101018772-B | Neuroactive compounds | PRANA BIOTECHNOLOGY LTD | 2012-10-10 | — | — | CN | disclosed |
| US-8084459-B2 | 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract | PRANA BIOTECHNOLOGY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
| US-20080119470-A1 | Neurologically-Active Compounds | XOMA TECHNOLOGY LTD. | 2008-05-22 | — | — | US | disclosed |
| CN-101018772-A | Neuroactive compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2007-08-15 | — | — | CN | disclosed |
| US-4873357-A | Trifluoro acetyl-cyano-aniline intermediates for dopamine-βhydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-10 | — | — | US | disclosed |
| US-4719223-A | ENZYME INHIBITORS, HYPOTENSIVE, CARDIOTONIC DIURETIC | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0221778-A2 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119470-A1 | Neurologically-Active Compounds | ACHE, PSEN1, PSEN2 | MEN1 1779/4885KMT2A 1955/4885TDP1 225/4885 |
| US-20110312995-A1 | BRIDGED AND FUSED HETEROCYCLIC ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | MEN1 3869/4885KMT2A 3265/4885TDP1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.